With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...
The FDA cited in its letter to SK several issues with the risk and benefit information presented about Xcopri in the ad. For ...
But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback